We are investigating the long-term safety and effects of DNL310 in patients with MPS II. This study looks at how well the treatment works for cognitive and physical development.
Health conditions and diseases that the clinical trial is designed to study and treat.
Hunter's syndrome (Mucopolysaccharidosis Type II) is a rare genetic disorder caused by the deficiency of an enzyme needed to break down certain sugars, leading to a buildup of these substances in the body. This can result in various symptoms affecting physical and mental development.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
